Goodbye Needles: New Urine Test Could Cut Unnecessary Prostate Cancer Biopsies by 53%

By: | February 5th, 2025

Image by Pixabay

Urine-Based Test Detects Aggressive Prostate Cancer

Conventional prostate cancer screening methods, such as blood tests, MRIs, and biopsies, can be uncomfortable and sometimes lead to the overdiagnosis of low-grade cancers. However, a new study confirms that a urine-based test can provide the same level of accuracy without requiring invasive procedures, paving the way for a more convenient at-home testing option.

Prostate cancer is the second leading cause of cancer-related deaths among American men, following lung cancer, with approximately one in 44 men dying from the disease. Globally, it is the most common cancer among men in 118 countries. When detected early, it is often highly treatable.

Breakthrough Urine Test: MyProstateScore 2.0 (MPS2)

Researchers at the University of Michigan have developed a new urine-based test called MyProstateScore 2.0 (MPS2), which accurately identifies men with aggressive prostate cancer. This test analyzes 18 different genes linked to high-grade prostate cancer.

Key Findings:

  • High Accuracy – MPS2 demonstrated strong accuracy in detecting aggressive prostate cancer.
  • Reduced Biopsies – The test could help avoid up to 53% of unnecessary biopsies, reducing complications and lowering healthcare costs.
  • Non-Invasive – As a simple urine test, MPS2 offers a more comfortable and convenient alternative to traditional screening methods.

Why It Matters:

This breakthrough has the potential to revolutionize prostate cancer diagnosis by helping doctors focus treatment on those who truly need it, while sparing low-risk patients from unnecessary procedures. By improving accuracy and reducing invasiveness, MPS2 could transform prostate cancer screening and care.

Nidhi Goyal

Nidhi is a gold medalist Post Graduate in Atmospheric and Oceanic Sciences.

More articles from Industry Tap...